White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices.

The present study is focused on the sensitive determination of newly FDA-approved glucagon-like-peptide agonists semaglutide (SEM) and tirzepatide (TIR). Direct, selective and label-free spectrofluorometric method was proposed and validated (according to ICH guidelines) for determination SEM and TIR in their pure form, newly approved pharmaceuticals and spiked human plasma. The developed method was based on measuring the native fluorescence of SEM and TIR in ethanol at 294.8 and 303 nm after being excited at 216 and 225 nm for SEM and TIR in order. The method sensibility allowed the quantification of both drugs in nano-scale up to 10 ng/mL. Several experimental variables including solvent type, surfactant, and pH were optimized after several attempts to get the best sensitivity for both drugs. The mean recovery percentage of SEM was compared and found in agreement with the reported method using student's t-test and the variance ratio F-test. Additionally, the greenness and whiteness profiles for this approach were evaluated using the GAPI, AGREE, and RGB algorithm; the positive results supported its use as great candidates for successful implementation in quality control labs and the pharmaceutical analysis companies.

Taguchi Approach for Optimization of a Green Quantitative 1H-NMR Practice for Characterization of Levetiracetam and Brivaracetam in Pharmaceuticals.

BACKGROUND: Recently, quantitative nuclear magnetic resonance (qNMR) competes with separation techniques such as high performance liquid chromatography (HPLC) and capillary electrophoresis for quantification purposes when dealing with molecules that lack a chromophore. OBJECTIVE: The advantages of the proton nuclear magnetic resonance spectroscopy as a revolutionary quantitative analysis method were exploited aimed at simple and green assessment of two racetams, namely levetiracetam (LEV) and brivaracetam (BRV), as a new family of antiepileptic medications with a unique mechanism of action. The developed technique was effectively used to determine LEV in Keppra tablets and BRV in laboratory-prepared tablets without interfering with the ordinarily suspected excipients. METHOD: A Taguchi approach was applied as a powerful and user-friendly statistical technique for optimization of the qH1NMR experimental design for both drugs. The optimum acquisition conditions were number of scans 32, pulse angle 20°, and relaxation delay of 40 s for LEV and number of scans 128, pulse angle 90°, and relaxation delay of 1 s for BRV. NMR spectra were obtained by means of phloroglucinol as an internal standard and dimethyl sulfoxide-d6 as a solvent. RESULTS: The diagnostic doublet of doublet quantitative signals at 4.3 and at 4.2 ppm were chosen to estimate LEV and BRV, respectively. The recovery of both drugs was quantified through the range of 0.1-12 mg/mL. The limits of detection were 0.013, 0.0013 and the limits of quantitation were 0.04, 0.0039 mg/mL for LEV and BRV correspondingly. CONCLUSIONS: The suggested technique was fully validated according to ICH guidelines and proved to be an eco-friendly practice by means of three different assessment tools, including the green analytical procedures index, national environmental methods index, and analytical eco-scale. qH1NMR should be considered a green alternative for quantification and quality control assessment of pharmaceuticals. HIGHLIGHTS: This research represents the first simple, quick, and green alternative method for determination of both racetams in their pharmaceuticals.

Multiobjective optimization of microemulsion- thin layer chromatography with image processing as analytical platform for determination of drugs in plasma using desirability functions.

A new platform was developed for determination of drugs in plasma without extraction or instrumental analysis just using TLC, smart phone digital camera and free image processing software. Lamotrigine, antiepileptic drug was used as model analyte. The proposed platform depends on using oil-in-water (O/W) microemulsion to isolate the drug from plasma proteins and using water-in-oil (W/O) microemulsion as mobile phase for TLC which results in complete separation between lamotrigine and plasma as viewed under UV lamp. The composition of both microemulsions was optimized using Taguchi orthogonal array and Plackett- Burman design. The optimal (O/W) microemulsion predicted composition was 0.01 mL Butyl acetate, 4 mL butanol, 0.925 gm SDS and 8.6 mL water while the (W/O) mobile phase microemulsion was 9 mL Butyl acetate, 1 mL butanol, 0.25 gm SDS, 0.25 mL water. Separation was carried out on a silica gel 60F-254 plate eluted with the (W/O) microemulsion in about 30 min development time. The images of TLC plates were processed using 4 different programs, by comparing their results it was found that "integrated density" measured by Fiji software was the most accurate response that could measure the concentration of lamotrigine in spiked plasma in the range of (20-200) ng/spot. This method was applied also for determination of lamotrigine in lamictal® tablet dosage form using the same mobile phase. The precision of the method was satisfactory; the maximum value of relative standard deviations did not exceed 1.5%. While the accuracy was proved by the low values of % error and high values of recovery.

Simultaneous determination of enalapril and hydrochlorothiazide in pharmaceutical preparations using microemulsion liquid chromatography.

A rapid high-performance liquid chromatography procedure for analytical quality control of mixture containing enalapril maleate (ENM) and hydrochlorothiazide (HCT) in their pharmaceutical preparations was developed using a microemulsion as an eluent. The separation was performed on a column packed with cyano-bonded stationary phase adopting UV detection at 210 nm using a flow rate of 1 mL/min. The optimized microemulsion mobile phase consisted of 0.2 M sodium dodecyl sulfate, 1% octanol, 10% n-propanol and 0.3% triethylamine in 0.02 M phosphoric acid, and pH was adjusted at 3.5. The proposed method was found to be linear over the concentration ranges 1-100 and 0.05-5 µg/mL for ENM and HCT, respectively with a correlation coefficient of 0.9999 for both drugs. The developed method was validated in terms of specificity, linearity, lower limit of quantification, lower limit of detection, precision and accuracy. The proposed method is rapid (5 min), reproducible (relative standard deviation <2.0%) and achieves a satisfactory resolution between ENM and HCT (resolution factor = 3.62). The mean recoveries of the analytes in tablets were in agreement with those obtained from a comparison method, as revealed by statistical analysis of the obtained results using Student's t-test and the variance ratio F-test.

Microemulsion liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe in their combined dosage forms.

A rapid HPLC procedure using a microemulsion as an eluent was developed and validated for analytical quality control of antihyperlipidemic mixture containing simvastatin (SIM) and ezetimibe (EZT) in their pharmaceutical preparations. The separation was performed on a column packed with cyano bonded stationary phase adopting UV detection at 238 nm using a flow rate of 1 mL/min. The optimized microemulsion mobile phase consisted of 0.2 M sodium dodecyl sulphate, 1% octanol, 10% n-propanol, and 0.3% triethylamine in 0.02 M phosphoric acid at pH 5.0. The developed method was validated in terms of specificity, linearity, lower limit of quantification (LOQ), lower limit of detection (LOD), precision, and accuracy. The proposed method is rapid (8.5 min), reproducible (RSD < 2.0%) and achieves satisfactory resolution between SIM and EZT (resolution factor = 2.57). The mean recoveries of the analytes in pharmaceutical preparations were in agreement with those obtained from a reference method, as revealed by statistical analysis of the obtained results using Student's t-test and the variance ratio F-test.

Simultaneous determination of norfloxacin and tinidazole binary mixture by difference spectroscopy.

A simple and rapid difference spectroscopic method was developed for the simultaneous determination of binary mixture of norfloxacin (NF) and tinidazole (TZ) without prior separation. The proposed method depends upon measuring the absorbance of NF at 291.6 nm which is the zero crossing point on the difference spectra of TZ in 0.1 N NaOH vs. 0.1 N HCl. Similarly, the absorbance of TZ was measured at 344.4 nm which is the zero crossing point on the difference spectra of NF. Beer's law was obeyed in the concentration range of 2-20 and 5-50 µg/mL for NF and TZ, respectively. The lower limits of detection (LOD) of NF and TZ are 0.23 and 0.36 µg/mL, respectively, while the lower limits of quantification (LOQ) of NF and TZ were 0.70 and 1.08 µg/mL, respectively. The precision of the method was satisfactory; the maximum value of relative standard deviations did not exceed 1.5% (n=10). The accuracy, expressed as recovery is between 98.25 and 101.8% with relative error of 0.29 and 0.23 for NF and TZ, respectively. The proposed method was successfully applied for the determination of both drugs in bulk powder, laboratory prepared mixture and commercial dosage forms such as tablets without interference from the commonly encountered excipients and additives. The results obtained are in good agreement with those obtained by the reference methods.

Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde.

A sensitive, simple and selective spectrofluorimetric method was developed for the determination of Lamotrigine (LMT) in pharmaceutical formulations and biological fluids. The method is based on reaction of LMT with o-phthalaldehyde in presence of 2-mercaptoethanol in borate buffer of pH 9.8 to yield a highly fluorescent derivative that is measured at 448 nm after excitation at 337 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized. The fluorescence-concentration plot was rectilinear over the range of 0.1-1.0 microg ml(-1) with lower limit of detection (LOD) 0.02 microg ml(-1) and limit of quantification (LOQ) 0.06 microg ml(-1) respectively. The proposed method was successfully applied to the the analysis of commercial tablets. Statistical comparison of the results obtained by the proposed and reference method revealed no significant difference in the performance of the two methods regarding the accuracy and precision respectively. The proposed method was further extended to the in-vitro and in-vivo determination of the drug in spiked and real human plasma. The mean percentage recoveries in spiked and real human plasma (n = 3) were 95.78 +/- 1.37 and 90.93 +/- 2.34 respectively. Interference arising from co-administered drugs was also studied. A proposal for the reaction pathway with o-phthalaldehyde was postulated.

Simultaneous determination of ritodrine and isoxsuprine using coupling technique of synchronous fluorimetry and H-point standard addition method.

Simultaneous determination of two structurally related ss(2) adrenergic receptor agonists namely, Ritodrine HCl (RTH) and Isoxsuprine HCl (ISP) was performed using coupling technique of synchronous fluorimetry and H-point standard addition method. Under optimum conditions, linear determination ranges were 1.48 - 14.80 x 10(-6) mol L(-1) and 1.54 - 15.44 x 10(-6) mol L(-1) for ISP and RTH respectively. RTH and ISP could be determined simultaneously without interference from each other when their concentration ratio varies from 5:1 to 1:5 in the mixed sample. The proposed method was applied to the determination of RTH and ISP in synthetic mixture of pharmaceutical samples, the accuracy and precision of the results were satisfactory.

Simultaneous determination of loratadine and desloratadine in pharmaceutical preparations using liquid chromatography with a microemulsion as eluent.

A rapid HPLC procedure for analytical quality control of pharmaceutical preparations containing the antihistaminic drug substance loratadine and/or its analog desloratadine (which is also an active metabolite of loratadine) was developed using a microemulsion as the eluent. The separation was performed on a column packed with cyanopropyl bonded stationary phase adopting UV detection at 247 nm using a flow rate of 1 ml/min. The optimized microemulsion mobile phase consisted of 0.1M sodium dodecyl sulphate, 1% octanol, 10% n-propanol and 0.3% triethylamine in 0.02 M phosphoric acid, pH 3.0. The developed method was validated in terms of specificity, linearity, lower limit of quantification, lower limit of detection, precision and accuracy. With the proposed method satisfactory resolution between loratadine and desloratadine (resolution factor=3.85). The method requires a minimum of sample handling and is rapid (10 min), and reproducible (R.S.D.<2.0%). The mean recoveries of the analytes in pharmaceutical preparations were in agreement with those obtained from a reference method, as revealed by statistical analysis of the obtained results using the Student's t-test and the variance ratio F-test. Pseudoephedrine, the co-formulated drug substance, did not interference with the assay and was successfully separated using the developed HPLC method.

Spectrofluorometric determination of citalopram in pharmaceutical preparations and spiked human plasma using organized media.

The native fluorescence of citalopram (CIT) was obtained in citrate buffer of pH 6.5 with and without beta-cyclodextrin (beta-CD) or sodium dodecyl sulfate (SDS) as fluorescence enhancers at 305 nm using 242 nm for excitation. Micellar systems of ionic and nonionic surfactants were investigated by measuring the fluorescence intensity of the analyte-surfactant system. In slightly acidic aqueous solution of pH 6.5, CIT was better incorporated in CDs and SDS micelles. The luminescence emission from CIT was found to be greatly enhanced by SDS micelles. The fluorescence intensity enhancements in CDs medium and in SDS as ionic surfactant relative to slightly acidic aqueous solution were 125 and 250%, respectively. Organized media-enhanced spectroflourometric methods were developed for the determination of CIT, in pure form as well as in pharmaceutical preparations. The fluorescence intensity-concentration plots were rectilinear over the ranges 0.06 to 0.64, 0.04 to 0.40, and 0.02 to 0.26 microg/mL with lower detection limits of 0.02, 0.01, and 0.007 microg/mL, either in citrate buffer only or in beta-CD and SDS as organized media, respectively. Furthermore, the high sensitivity attained by using SDS as organized medium allowed in vitro spectrofluorometric determination of CIT in spiked human plasma. Interference from endogenous amino acids has been overcome by using the solid-phase extraction technique; the mean recovery (n = 5) was 100.1+/-0.8%

Analysis of flunarizine in the presence of some of its degradation products using micellar liquid chromatography (MLC) or microemulsion liquid chromatography (MELC)--application to dosage forms.

The separation of flunarizine hydrochloride (FLZ) and five of its degradation products--1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine, 4-oxide (A), bis(4-fluorophenyl)methanone (B), bis(4-fluorophenyl)methanol (C), 1-(3-phenyl-2-propenyl)piperazine(D), and 1-[bis-4-fluorophenyl) methyl] piperazine (E)--could be accomplished by reversed phase liquid chromatography using either micellar or microemulsion mobile phases. Cyanopropyl-bonded stationary phase has been used with UV detection at 254 nm. Microemulsion mobile phase consisting of 0.15 M SDS, 10% n-propanol, 1% n-octanol, and 0.3% triethylamine in 0.02 M phosphoric acid of pH 7.0, has been used for the separation of FLZ and its degradation products (B, C, D, and E). Micellar mobile phases consisting of 0.15 M sodium dodecyl sulphate (SDS), 10% n-propanol, 0.3% triethylamine (TEA) in 0.02 M phosphoric acid of pH values either 4.0 or 6.8 have been used for the separation of FLZ from its degradation products, i.e. either from (B, C, D, and E) or from (A, B, C, and D), respectively. Micellar liquid chromatography (MLC) was applied to the determination of FLZ in pure form as well as in dosage forms; the calibration graph was linear over the concentration range of 0.15-50 microg/mL with detection limit of 0.02 microg/mL (4.19 x 10(-8)M).

Determination of lisinopril in dosage forms and spiked human plasma through derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) followed by spectrophotometry or HPLC with fluorimetric detection.

Two sensitive, simple and specific methods based on spectrophotometry and reversed-phase HPLC with fluorimetric detection are described for the determination of lisinopril in dosage forms as well as in spiked human plasma using solid phase extraction (SPE) procedures. Both methods are based on the derivatization of lisinopril with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) in borate buffer of pH 9 to yield a yellow, fluorescent product. The spectrophotometric method depends on measuring the formed yellow color at 470 nm after optimization of the reaction conditions. The HPLC method is based on measurement of the derivatized product using fluorescence detection at 540 nm (excitation at 470 nm). The separation of the derivatized drug, the excess reagent and the internal standard (bumetanide) was performed on a reversed-phase ODS column using isocratic elution with methanol-0.02 M sodium dihydrogen phosphate, pH 3.0 (55:45, v/v) at a flow rate of 1.0 ml/min. The calibration graphs were linear over the concentration ranges 2-20 or 0.02-3.2 microg/ml of lisinopril with minimum detectability of 0.3 and 0.008 microg/ml (6.1 x 10(-7) and 1.7 x 10(-8)M) for the spectrophotometric and the HPLC methods, respectively. The proposed methods were applied without any interference from the tablet excipients for the determination of lisinopril in dosage forms, either alone or co-formulated with hydrochlorothiazide. Furthermore, the use of the HPLC method was extended to the in vitro determination of the drug in spiked human plasma. Interference from endogenous amino acids has been overcomed by using the solid phase extraction technique, the percentage recovery (n=6) was 101.6+/-3.35.

Spectrophotometric determination of propranolol in formulations via oxidative coupling with 3-methylbenzothiazoline-2-one hydrazone.

A simple spectrophotometric method has been developed for the determination of propranolol hydrochloride in pure as well as in dosage forms. The method is based on the oxidative coupling reaction with 3-methylbenzothiazoline-2-one hydrazone. A mixture of an acidic solution of the chromogenic agent and the drug upon treatment with ceric ammonium sulfate produces an orange color peaking at 496 nm. The absorbance-calibration plot was linear over the range 1-10 microg/ml with minimum detectability (S/N=2) of 0.1 microg/ml (3.38x10(-7) M). The molar absorbitivity was 3.195x10(3) l/M/cm with correlation coefficient (n=10) of 0.9999. The different experimental parameters affecting the development and stability of the color were carefully studied and optimized. The proposed method was applied successfully to the determination of propranolol in its dosage forms. A proposal of the reaction pathway was presented.